Durvalumab (small cell lung cancer, non-advanced) – Addendum to Project A25-96

Report documents

1. Addendum

   Durvalumab (kleinzelliges Lungenkarzinom, nicht fortgeschritten) – Addendum zum Projekt A25-96

   published on

   22.01.2026

   Document type

   PDF document, 239 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G25-39

   Download file : Addendum (PDF document, 239 kB, DE, not accessible)

Additional information

Project details

Project no.

G25-39

Commission

Commission awarded on 09.12.2025 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

DOI

https://doi.org/10.60584/G25-39

Connected Projects

1. Dossier assessment

   Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V

   Project no.

   A25-96

   Last updated

   22.01.2026

   Status: Commission completed